Hearts & Minds Blog

Bringing My Life’s Work to Esperion

Tricia Mullins

Executive Director, Advocacy & Professional Relations

As February comes to a close, we reflect on the importance of recognizing American Heart Month, a time dedicated to… more

Cost-Effective Innovation

Tim Mayleben

President and Chief Executive Officer

By now you’ve read the headlines about the high cost of the new cholesterol lowering drugs.  We’ve been bombarded with… more

NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density… more

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than… more

Looking Back on a Successful 2013 and a Glance Ahead at a Promising 2014

Tim Mayleben

President and Chief Executive Officer

Esperion had an incredible year in 2013 with more successes, both clinically and financially, than in any other year since… more

Posted In: Company News